{
  "id": 7407005,
  "title": "Study reveals how a blood biomarker tracks response to lecanemab in early Alzheimer's disease",
  "url": "https://urgent.news/2026/09/14/study-reveals-how-a-blood-biomarker-tracks-response-to-lecanemab-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T22:00:02.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-reveals-blood-biomarker-tracks-response.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "A recent study conducted by researchers from Korea University College of Medicine has found that plasma phosphorylated tau 217 (p-tau217), a blood-based biomarker associated with Alzheimer's disease pathology, can serve as an early marker of response to lecanemab treatment. The prospective real-world study followed 153 patients receiving lecanemab, measuring plasma p-tau217 at baseline and during treatment to assess cognitive measures such as the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating–Sum of Boxes (CDR-SB). The researchers identified two distinct p-tau217 response patterns, with patients exhibiting greater reductions in p-tau217 showing more favorable cognitive trajectories. Notably, baseline hypertension was independently associated with a weaker p-tau217 response. The findings suggest that repeated p-tau217 measurements could provide valuable information about biological treatment response during lecanemab therapy, potentially allowing for less invasive, cost-effective, and accessible monitoring compared to repeated PET imaging. However, larger, multicenter studies with longer follow-up are required to validate these response patterns and establish clinically meaningful thresholds.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}